ICICI Bank Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IBN research report →
Price Chart
About the company
ICICI Bank Limited, a prominent financial institution with its various subsidiaries, delivers a comprehensive suite of banking and financial solutions. These services cater to both individual consumers (retail) and corporate entities, spanning operations across India and global markets. Its business activities are organized into distinct segments: Retail Banking, Wholesale Banking, Treasury operations, other banking functions, Life Insurance, and additional miscellaneous areas.
- CEO
- Sandeep Bakhshi
- IPO
- 2000
- Employees
- 124,324
- HQ
- Mumbai, MA, IN
Get TickerSpark's AI analysis on IBN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $100.12B
- P/E
- 17.13
- Fwd P/E
- 0.17
- PEG
- 3.54
- P/S
- 3.22
- P/B
- 2.53
- EV/EBITDA
- 12.32
- Div Yield
- 0.89%
- Gross Margin
- 68.53%
- Op Margin
- 26.46%
- Net Margin
- 18.76%
- ROE
- 15.71%
- ROIC
- 5.28%
Latest fiscal year · YoY change
- Revenue
- $3.12T+6.0%
- Gross Profit
- $2.17T+8.4%
- Op Income
- $773.20B
- Net Income
- $542.08B+6.2%
- EPS
- $151.78+4.8%
- OCF Growth
- -18.1%
- FCF Growth
- -17.8%
- 52W High
- $33.03
- 52W Low
- $25.08
- 50D MA
- $29.29
- 200D MA
- $28.64
- Beta
- 0.23
- RSI (14)
- 44
- Avg Volume
- 5.52M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ICICI Bank delivered another strong quarter with double-digit profit growth, robust loan and deposit expansion, and stable margins, while management sounded confident about sustaining momentum but cautious on near-term FCNR and ECL transitions.· July 18, 2026
- Profit before tax excluding treasury rose 20.9% YoY to INR 189.75 billion; PAT rose 15.9% YoY to INR 148.05 billion.
- Loan growth was strong at 19.6% YoY and 5% sequentially, led by rural, business banking, and corporate segments.
- NIM stayed steady at 4.36%, supported by a healthy funding franchise and disciplined pricing.
- Asset quality remained manageable: net NPA ratio was 0.35% and provisions were INR 12.60 billion, or 0.32% of average advances.
- Management sees continued growth opportunities, but FCNR mobilization could pressure NIMs and ECL transition timing remains uncertain.
ICICI Bank reported PBT excluding treasury of INR 189.75 billion, up 20.9% YoY; core operating profit was INR 202.35 billion, up 15.6% YoY; core operating profit excluding dividend from subsidiaries was INR 191.25 billion, up 18.3% YoY; and PAT was INR 148.05 billion, up 15.9% YoY. Net interest income increased 12.7% YoY and 6.1% sequentially to INR 243.84 billion, while NIM was 4.36% versus 4.32% in the previous quarter and 4.34% in Q1 of last year. Total deposits grew 14% YoY and 2.2% sequentially; average deposits grew 14% YoY and 6.1% sequentially; and the loan book grew 19.6% YoY and 5% sequentially. Net NPA ratio was 0.35% versus 0.33% in March 2026 and 0.41% in June 2025; gross NPA additions were INR 55.52 billion and net additions were INR 27.07 billion. Total provisions were INR 12.60 billion, or 6.2% of core operating profit and 0.32% of average advances; contingency provision stood at INR 131 billion, and CET1 was 16.19% with total capital adequacy ratio of 16.84%. Forward-looking commentary was that loan growth momentum remains strong, NIMs should stay range bound under current conditions, FCNR deposit mobilization is still early, and ECL transition impact is expected to be absorbed by provisioning buffers.
Sandeep Bakhshi framed the quarter around ICICI Bank’s strategy of growing profit before tax, excluding treasury, through a “360-degree customer-centric approach” across ecosystems and micro markets. He highlighted strong growth across deposits, loans, and profitability while emphasizing a strong balance sheet, prudent provisioning, and healthy capital. His tone was confident and upbeat, with a clear focus on sustainable and predictable returns rather than aggressive risk-taking.
Anindya Banerjee detailed broad-based operating strength: NII rose to INR 243.84 billion, NIM was 4.36%, fee income excluding treasury increased 16% YoY to INR 84.25 billion, and operating expenses rose 10.4% YoY. He noted provisions of INR 12.60 billion versus INR 18.15 billion a year ago, a contingency buffer of INR 131 billion, and a total provision pool of INR 229.63 billion excluding specific provisions on NPAs. He also flagged that FCNR deposits could be cost-effective at an all-in cost of roughly 630–640 bps after hedging, but may create some NIM pressure as the overseas balance sheet expands; on ECL, he said net worth impact should be absorbed by provisioning buffers, while recurring credit costs will likely rise across the sector.
Analysts focused on whether the current loan growth pace is sustainable, what FCNR mobilization means for margin/profitability, and whether the strong fee growth was repeatable. Management said system loan growth has picked up over the last few quarters, momentum remains strong, and FCNR mobilization is still early with no formal target; they also said the scheme should be competitive versus wholesale lending rates. On margins, management said NIMs should remain range bound under current conditions, but FCNR-driven balance sheet expansion could create some pressure over time. On asset quality, management said agricultural remediation is underway and being validated before any write-back of provisions, and on ECL they expect the transition impact to be absorbed by buffers.
The call showed broad-based momentum: loans, deposits, NII, fee income, and profits all grew strongly, while asset quality and capital remained solid. Management repeatedly said demand looks healthy across segments, including corporate, business banking, retail, and overseas branches, and that the franchise has room to gain share.
There are a few watchpoints: credit card growth is weak, FCNR mobilization could weigh on NIMs, and the timing of any agri provision write-back remains unclear. Management also acknowledged that ECL adoption will raise recurring provisions, even if the balance-sheet transition impact is expected to be absorbed by existing buffers.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 100.2%
- Shares Outstanding
- 3.58B
- Float Shares
- 3.58B
of shares held by institutions
535 13F filers
Buy/sell ratio 0.76. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for IBN, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lisa C. McClainHouse · MI09 | Sell | Aug 13, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 24, 25 | Filing → |
| Josh S. GottheimerHouse · NJ05 | Sell | Sep 20, 24 | Filing → |
| Josh S. GottheimerHouse · NJ05 | Sell | Sep 23, 24 | Filing → |
| Josh S. GottheimerHouse · NJ05 | Sell | Jun 21, 24 | Filing → |
| Josh S. GottheimerHouse · NJ05 | Sell | Feb 1, 23 | Filing → |
| Peter MeijerHouse · MI03 | Sell | Feb 17, 21 | Filing → |
| Greg GianforteHouse · MT00 | Sell | Aug 4, 20 | Filing → |
| Donna ShalalaHouse · FL27 | Sell | Jun 24, 19 | Filing → |
| Greg GianforteHouse · MT00 | Buy | Jan 13, 20 | Filing → |
| Greg GianforteHouse · MT00 | Sell | Jan 3, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Morgan Stanley | 54.40M | ▲ 6.28M |
| Wcm Investment Management, LLC | 51.51M | ▼ 735.77K |
| Gqg Partners LLC | 30.90M | ▼ 46.47M |
| Temasek Holdings (Private) Ltd | 29.20M | 0 |
| Invesco Ltd. | 24.41M | ▲ 2.42M |
| Jpmorgan Chase & Co | 22.99M | ▲ 9.23M |
| Robeco Institutional Asset Management B.V. | 21.15M | ▲ 1.31M |
| Schroder Investment Management Group | 15.76M | ▲ 7.39M |
| Fil Ltd | 13.68M | ▼ 463.01K |
| Dimensional Fund Advisors LP | 10.38M | ▼ 484.46K |
| Capital International Investors | 9.31M | ▼ 2.46M |
| Ninety One Uk Ltd | 9.18M | ▼ 467.81K |
Held by 183 ETFs
Biggest fund positions in IBN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 26 | Banerjee Anindya | other | 125,600 |
| May 1, 26 | Banerjee Anindya | other | 125,600 |
| May 5, 26 | Batra Sandeep | other | 20,125 |
| May 5, 26 | Batra Sandeep | other | 20,125 |
| May 5, 26 | Gupta Ajay K | other | 18,200 |
| May 5, 26 | Gupta Ajay K | other | 41,400 |
| May 5, 26 | Gupta Ajay K | other | 41,400 |
| May 5, 26 | Gupta Ajay K | other | 18,200 |
| Apr 24, 26 | Jha Rakesh | sell | 45,000 |
| Apr 28, 26 | Bakhshi Sandeep | other | 53,900 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IBN coverage
Recent articles, reports, and earnings notes.
No research on IBN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IBN report →IBN to Serve as Media Sponsor of The ThinkEquity Conference 2026
globenewswire.com · Oct 2
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
globenewswire.com · Sep 30
ICICI Bank (NYSE:IBN) vs. Citizens (NASDAQ:CIZN) Head-To-Head Survey
defenseworld.net · Sep 30
IBN Announces Latest Episode of The MiningNewsWire Podcast featuring Dr. Bo Møller Stensgaard, President of Greenland Mines Ltd.
globenewswire.com · Sep 24
IBN Initiates Coverage of Apimeds Pharmaceuticals US, Inc.
globenewswire.com · Sep 18
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.
globenewswire.com · Sep 18
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd.
globenewswire.com · Sep 10
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Galiano Tiramani, Co-CEO of BOXABL Inc.
globenewswire.com · Sep 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.